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ABSTRACT
DNA damage is a common hazard that all cells have
to combat. Saccharomyces cerevisiae HMO2 is
a high mobility group protein (HMGB) that is a
component of the chromatin-remodeling complex
INO80, which is involved in double strand break
(DSB) repair. We show here using DNA end-joining
and exonuclease protection assays that HMO2
binds preferentially to DNA ends. While HMO2
binds DNA with both blunt and cohesive ends, the
sequence of a single stranded overhang significantly affects binding, supporting the conclusion
that HMO2 recognizes features at DNA ends.
Analysis of the effect of duplex length on the
ability of HMO2 to protect DNA from exonucleolytic
cleavage suggests that more than one HMO2 must
assemble at each DNA end. HMO2 binds
supercoiled DNA with higher affinity than linear
DNA and has a preference for DNA with lesions
such as pairs of tandem mismatches; however,
comparison of DNA constructs of increasing
length suggests that HMO2 may not bind stably as
a monomer to distorted DNA. The remarkable ability
of HMO2 to protect DNA from exonucleolytic
cleavage, combined with reports that HMO2
arrives early at DNA DSBs, suggests that HMO2
may play a role in DSB repair beyond INO80
recruitment.
INTRODUCTION
All organisms depend on eﬃcient repair of DNA double
strand breaks (DSBs) to maintain genomic stability (1,2).
The most accurate repair pathway is homologous recombination (HR), which is mainly active during S and G2 as
it depends on the presence of sister chromatids, while the
more error prone non-homologous end-joining (NHEJ) is
active throughout the cell cycle (2). Both repair pathways

must negotiate DNA that is packaged into chromatin,
and chromatin remodeling is therefore critical to DNA
repair (3–7).
The ATP-dependent chromatin remodeling complex
INO80 has been recently shown to participate in DSB
repair in yeast (3,8–11). The INO80 complex is recruited
to the DSB by interaction with the damage-induced
phosphorylated histone H2A (g-H2AX), a phenomenon
that requires the high mobility group protein (HMGB)
HMO2 (also known as NHP10). HMO2 has been
reported to be responsible for interaction with g-H2AX
and its inactivation results in reduced INO80 recruitment
to the DSB, but not to impaired chromatin remodeling
activity (3). Since H2A phosphorylation is thought to be
an early response to DSB formation, INO80—and hence
HMO2—may contribute to DSB repair by both pathways.
High mobility group (HMG) proteins are non-histone
chromosomal proteins that are classiﬁed into three
groups, HMGA, HMGB and HMGN depending on
their DNA-binding characteristics (12,13). HMGB
proteins contain one or more HMG boxes, an 80
amino-acid sequence (13,14), and are further classiﬁed
into two groups depending on sequence speciﬁcity; the
sequence-speciﬁc family consists of transcription factors
such as lymphoid enhancer factor (LEF) and sexdetermining factor (SRY), while the non-sequence
speciﬁc family includes HMGB1, HMGB2 and yeast
homologs NHP6A and NHP6B (12,14–19). The HMG
box is composed of three a-helices which adopt an ‘L’
shaped fold (14–17,19–21). Binding to the DNA occurs
through the minor groove by partial intercalation of
hydrophobic amino acids, resulting in DNA bending
(12,18,21), and HMGB proteins preferentially bind to
distorted DNA such as cisplatin-modiﬁed DNA (22,23).
HMGB proteins participate in stabilizing chromatin
structure and play a role in DNA-dependent processes
such as recombination and transcription by facilitating
nucleoprotein complex assembly. HMGB proteins have
also been suggested to contribute to DNA repair, as
evidenced for example by DNA end-joining in vitro in
the presence of DNA ligase (24–27).
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MATERIALS AND METHODS
Cloning, overexpression and puriﬁcation of protein
The gene-encoding HMO2 was ampliﬁed from yeast
genomic DNA using primers NHP10F 50 -CACATAAG
CATATGTCAGTTGAA-30 and NHP10R 50 -CGTCTT
ACCATATGTTCAAAGAA-30 (NdeI sites underlined)
and cloned into the NdeI site of pET14b, resulting in
expression of HMO2 with an N-terminal His6-tag.
pET14b-HMO2 was transformed into Escherichia coli
Rosetta Blue and expression of HMO2 was induced by
addition of 1 mM isopropyl-b-D-thiogalactopyranoside
(IPTG) at A600 of 0.2 and induction was carried out
for 4 h. Cells were pelleted and then resuspended in lysis
buﬀer pH 7.5 (50 mM NaxHyPO4, 300 mM NaCl, 10 mM
imidazole, 20% glycerol, 1 mM 2-mercaptoethanol and
1 mM phenylmethylsulfonyl ﬂuoride (PMSF)). Cells were
disrupted by sonication. The nucleic acids were digested
by adding 2 ml of 2000 U/ml of DNaseI (New England
Biolabs) and incubated on ice for 1 h. To the lysate,
0.01% of Triton X-100 was added and the solution was
incubated on ice for 1 h and then centrifuged at 6000  g
for 20 min. The lysate was incubated with Ni-NTA
agarose beads for 1 h on ice. The nickel beads were equilibrated using lysis buﬀer prior to use. The beads were
washed using wash buﬀer pH 7.5 (50 mM NaxHyPO4,
300 mM NaCl, 20 mM imidazole, 20% glycerol, 1 mM
2-mercaptoethanol and 1 mM PMSF). Proteins were
eluted by gravity ﬂow using elution buﬀer pH 7.5
(50 mM NaxHyPO4, 300 mM NaCl, 250 mM imidazole,
20% glycerol, 1 mM 2-mercaptoethanol and 1 mM
PMSF). Pure HMO2 was quantitated using Coomassie
blue stained SDS–PAGE gels using bovine serum albumin
as standard as well as by Micro BCA Protein Assay Kit

(Pierce). At least three independent preparations
of HMO2 were used, indicating reproducibility of
the preparations. HMO1 was obtained as described
earlier (37).
Agarose gel retardation
One hundred nanograms of supercoiled or linear pGEM5
was incubated at 4 C with diﬀerent concentrations of
HMO2 in 10 ml reaction buﬀer (20 mM Tris pH 8.0,
0.1 M EDTA, 15 mM NaCl, 0.1 mM DTT and 0.01%
BRIJ 58). Complexes were resolved using 1% TBE
agarose gels using 0.5 TBE buﬀer (50 mM Tris borate,
1 mM EDTA) and visualized by ethidium bromide
staining.
DNA supercoiling
Supercoiled pUC18 was nicked using Nt.BstNBI
(New England Biolabs). One hundred nanograms of
nicked DNA was incubated with varying concentration
of HMO2, at room temperature for 1 h. Reactions were
initiated using 1 ml of 80 U/ml of T4 DNA ligase (New
England Biolabs) in presence of ligase buﬀer and
incubated at room temperature for 1 h. Reactions were
terminated using 1 ml stop buﬀer (5 mM EDTA, 1.1%
glycerol and 0.2 mg/ml proteinase K ﬁnal concentration)
and incubated at 37 C for 1 h. Samples were loaded on
1% TBE agarose gels and electrophoresed for 14 h
followed by staining with ethidium bromide. For determination of the direction of DNA supercoils produced by
HMO2, electrophoresis was performed in the presence
of 0.3 mg/ml chloroquine, using Bacillus subtilis HU as
a control.
Electrophoretic mobility shift assay
All oligonucleotides used for preparation of DNA
constructs were purchased and puriﬁed by denaturing
gel electrophoresis. Sequences are available in
Supplementary Table S1. Electrophoretic Mobility Shift
Assays (EMSAs) were performed using DNA duplex
and DNA with loops, nicks, gaps and overhangs. A
common 37-nt oligonucleotide was used to generate the
diﬀerent constructs. The top strand was 50 -end labeled
using T4 polynucleotide kinase (New England Biolabs)
and [g32P] ATP. The sequences of duplex as well as
DNA with nick, gap, loops and overhangs were as
described in (39) or presented in Supplementary Table
S1. Top and bottom strands were annealed by heating at
90 C and slowly cooling to room temperature. Similarly, a
50 bp DNA duplex and duplex with either a single or
tandem loops was generated by extending the 37 bp construct at both ends. Reactions contained 5 fmol of DNA
substrate and varying concentration of HMO2 in 10 ml
reaction buﬀer (20 mM Tris pH 8.0, 0.1 mM EDTA,
5 mM NaCl, 0.1 mM DTT, 0.01% BRIJ 58 and 0.1%
Triton X-100) and incubated at room temperature for
1 h. Experiments designed to compare diﬀerent DNA
constructs were performed side-by-side with the same
protein preparation. Samples were loaded on a prerun
8% polyacrylamide gel (39 : 1 acrylamide:bisacrylamide)
and electrophoresed using 0.5 TBE at 175 V for 2 h.
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Saccharomyces cerevisiae contains 10 HMGB proteins.
The single HMG box proteins NHP6A/B participate in
transcription by RNA polymerases II and III (18,28–30).
HMO1 and HMO2 are more similar to mammalian
HMGB proteins by having two HMG-like domains, Box
A and Box B. HMO1 has been shown to play a role in
plasmid maintenance and normal growth and it also
functions in the ribosomal RNA transcription system as
well as in regulating ribosomal protein expression (31–36).
In the 25-kDa HMO2, the two domains Box A and Box
B are followed by an acidic C-terminal tail in contrast to
HMO1, which has a lysine-rich tail. For both HMO1 and
HMO2, Box B corresponds to the mammalian Box B
while the N-terminal Box A bears little resemblance to
mammalian Box A. The HMO1 Box A domain has been
shown to contribute to DNA binding and bending (37,38).
We show here that HMO2 binds to DNA ends, both
blunt ends and overhangs, and that it protects DNA from
exonuclease digestion. Since protection of DNA ends
from exonucleolytic cleavage is essential to minimize loss
of genetic information before repair can be initiated, and
since HMO2 is thought to arrive early at DSBs in its
complex with INO80 components, our data suggests that
HMO2 may play a role in DSB repair beyond INO80
recruitment.
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Complexes were visualized using Amersham Biosciences
Storm Phosphorimager. Reactions were performed at
least in duplicate.
EMSA with four-way junctions

Competition assay
Five fmol 50-bp duplex DNA with loops and 4-mM of
HMO2 was incubated at room temperature for 1 h
in reaction buﬀer. Supercoiled or linear pGEM5
(0.5–50 fmol) was added and incubated at room temperature for 1 h; pGEM5 was linearized with NdeI or
AatII. Samples were electrophoresed on prerun 8% polyacrylamide gels. Complexes were viewed using Storm
Phosphorimager.
End-joining assay
Supercoiled pGEM5 was digested with NdeI or NaeI to
obtain DNA with a 2-nt 50 overhang or blunt ends, respectively. One hundred nanograms of linearized pGEM5
was incubated with varying concentrations of HMO2
or HMO1 at room temperature for 1 h. To this reaction,
1 ml of 400 U/ml of T4 DNA ligase was added and
incubated at room temperature for 1 h. Samples were
treated with exonuclease III (100 U/ml) at room temperature for 1 h. Reactions were terminated by adding 2 ml
stop buﬀer (5 mM EDTA, 1.1% glycerol and 0.2 mg/ml
proteinase K). Alternatively, supercoiled pET5a was
digested with BspHI, which creates a 4-nt 50 overhang.
One hundred nanograms of the linearized pET5a was
incubated with 2 mM HMO2. To this reaction 1 ml of
400 U/ml of T4 DNA ligase was added and incubated at
room temperature for 1 h. Reactions were terminated by
adding 2 ml of stop buﬀer. Samples were electrophoresed
on 1% TBE agarose gels and visualized by ethidium
bromide staining.
Using forward primer 50 -TGGGGTGCGAATTCTAA
TGAGT-30 and reverse primer 50 -GGCTTTACACTTTA
TGCTTCCG-30 , an extra EcoRI site was introduced into
plasmid pUC18 by PCR ampliﬁcation. The pUC18
variant was then digested with EcoRI to obtain 105 bp
DNA duplex with 50 -AATT extensions. The 105 bp
DNA was 50 -end labeled using T4 polynucleotide kinase
(New England Biolabs). One hundred femtomoles of
105 bp DNA was incubated with varying concentrations
of HMO2 or 100 nM B. subtilis HU at room temperature
for 1 h. To this reaction, 1 ml of 8 U/ml T4 DNA ligase was
added and incubated at room temperature for 1 h.
Samples were treated with exonuclease III (100 U/ml) at

Exonuclease III protection assay
Supercoiled pGEM5 was linearized with NdeI or NaeI to
yield DNA with 2-nt 50 overhangs or blunt ends, respectively. pET5a was digested with BspHI to produce 4-nt 50
overhang, pUC18 was digested with EcoRI, which also
produces a 4-nt 50 overhang, and a pcDNA3-derivative
was digested with ApoI, which likewise creates a 4-nt 50
overhang. pET5a was digested with ScaI and then PvuI
(which cuts supercoiled DNA only poorly), to yield a
blunt end and 2-nt 30 overhang, respectively. pRAD1
was digested with DraI to produce blunt ends. Fifty to
one hundred nanograms of linearized pGEM5, pET5a,
pUC18, pcDNA3-derivative and pRAD1 was incubated
at room temperature for 1 h with 2 mM HMO2 or
HMO1 previously dialyzed using dialysis buﬀer (50 mM
Tris pH 8.0, 50 mM NaCl and 20% glycerol). To each
reaction, 1 ml of 100 U/ml exonuclease III was added and
incubated at room temperature for 1 h. Reactions were
terminated by addition of 2 ml 10% SDS or by phenolextraction and ethanol precipitation (the latter in cases
where shorter DNA fragments are produced that may
co-migrate with SDS on the gels). Samples were
electrophoresed on 1% TBE agarose gels. Gels were
stained with ethidium bromide. All reactions were performed at least in duplicate, and pGEM5 digested with
NdeI to produce 50 -TA overhangs was included for comparison to other DNA constructs.
DNase I protection assay
One hundred nanograms of supercoiled or linearized
pGEM5 with blunt ends or overhangs were incubated at
room temperature for 1 h with 1 mM HMO2 in 10 ml
reaction buﬀer. One microliter of 0.1 U/ml DNaseI
(New England Biolabs) was added in presence of DNase
I buﬀer and incubated for 1, 2.5 and 5 min. Reactions were
terminated by adding 2 ml of stop buﬀer and incubating at
37 C for 30 min, followed by addition of 1 ml of 10% SDS.
Samples were electrophoresed on 1% TBE agarose gels.
Gels were stained with ethidium bromide.
RESULTS
HMO2 binds preferentially to distorted DNA compared
to linear duplex
While HMO2 has been proposed to interact with a
damage-induced histone H2A variant, conservation of
its Box B HMG-domain predicts direct DNA interaction.
To investigate a potential role in DNA interaction, HMO2
was therefore cloned from yeast genomic DNA and
overexpressed in E. coli. HMO2 was judged to be >95%
pure using Coomassie blue stained SDS–PAGE gels
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The sequence of the four-way junctions (4WJ) was
described in (39) and shown in Supplementary Table S1.
4WJ were obtained by 50 -end labeling one strand and
annealing the other three strands, followed by puriﬁcation
using native polyacrylamide gels. Complete annealing of
all strands was determined by comparing the electrophoretic mobility to that of annealed constructs lacking
one of the unlabeled strands. EMSA was performed as
described above using 5 fmol of DNA and varying concentration of HMO2 in reaction buﬀer. Final volume of
the reaction was 10 ml.

room temperature for 1 h. Reactions were terminated by
adding 2 ml stop buﬀer and 1 ml of 10% SDS and then
phenol chloroform extracted and ethanol precipitated.
Samples were loaded on a prerun 5% polyacrylamide gel
(39:1 acrylamide:bisacrylamide) and electrophoresed using
0.5 TBE at 175 V for 2 h. Complexes were visualized
using Amersham Biosciences Storm Phosphorimager.
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(Supplementary Figure S1). Consistent with the presence
of the classical Box B HMG domain, HMO2 binds both
supercoiled and linear DNA (Figure 1) suggesting nonsequence-speciﬁc binding as seen for other chromatinassociated HMGB proteins. While the mobility of
HMO2-associated linear DNA is gradually reduced as a
function of [HMO2] (Figure 1B), the mobility of
supercoiled DNA is enhanced at the highest [HMO2]
(Figure 1A), suggesting DNA compaction. Note also
that ethidium bromide staining of HMO2-bound DNA
is enhanced compared to free DNA, perhaps reﬂecting a
DNA unwinding by HMO2 that promotes dye-binding.
Like other HMGB proteins, HMO2 can constrain
DNA supercoils (Figure 1C). When nicked plasmid was
incubated with HMO2 in presence of T4 DNA ligase,
HMO2 was found to introduce supercoils to the relaxed
DNA. Electrophoresis in the presence of chloroquine
indicates the expected introduction of negative supercoils
by HMO2 (i.e., a slower migration of topoisomers in the
presence of chloroquine; data not shown). This is in consensus with other HMGB proteins which can supercoil
relaxed DNA (31). The ability of HMO2 to introduce
supercoils is consistent with the DNA compaction seen
on interaction with plasmid DNA (Figure 1A).
DNA binding was analyzed further using EMSA.
HMO2 does not form detectable complex with 50-bp
DNA duplex (Figure 2A) most likely reﬂecting that complexes are unstable and dissociate during electrophoresis
since association with longer DNA clearly leads to stable

Figure 2. HMO2 binds preferentially to DNA with pairs of tandem
mismatches. (A) EMSA of 50 bp DNA duplex and increasing concentrations of HMO2. (B, C) EMSA of 50 bp DNA duplex with a single
loop (tandem mismatches) and increasing concentrations of HMO2;
(B) loop composed of opposing AA nucleotides, (C) loop composed
of opposing CT nucleotides. (D) EMSA of 50 bp DNA duplex with
both AA and CT loops separated by 9 bp of duplex and increasing
concentrations of HMO2. Lanes 1, reactions with DNA only, lanes
2–8, reactions with 50, 100, 500, 1000, 2000, 3000 and 4000 nM
HMO2. (E) EMSA of four way junction DNA. Lane 1, 5 fmol of
four way junction only. Lanes 2–10, reactions with 50, 100, 500,
1000, 2000, 3000, 4000, 5000 and 6000 nM HMO2.

complex formation (Figure 1). Mammalian HMGB was
previously shown to bind preferentially to 37 bp DNA
containing a pair of loops (tandem mismatches) separated
by 9 bp of duplex (40). Using the same set of mismatches
in the context of 50 bp duplex (Supplementary Table S1),
HMO2 was seen to form a single stable complex (Figure
2D) indicating preferred binding to the looped DNA construct. Notably, association with the tandem-loop construct leads to enhanced complex formation compared
to 50 bp DNA with a single loop (Figure 2B and C),
and binding to the 50 bp duplex containing the CT loop
(in which the sequence of the bottom strand contains a
30 -CT-50 -sequence, resulting in identical opposing bases;
Figure 2C) is more stable than the 50 bp duplex with
AA loop (Figure 2B), perhaps indicating that the
sequence of the nucleotides at the loop results in diﬀerential DNA distortion, which in turn aﬀects HMO2 binding
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Figure 1. Interaction of HMO2 with plasmid DNA. (A, B) Agarose gel
retardation of 100 ng plasmid DNA titrated with HMO2. (A) Reactions
with supercoiled pGEM5. Lane 1, DNA only, lanes 2–7 with 1.0–6.0 mM
HMO2. (B) Reactions with linearized pGEM5. Lane 1, DNA only, lanes
2–6 with 1.0–5.0 mM HMO2. (C) HMO2 supercoils relaxed DNA. Lane 1,
100 ng supercoiled pUC18 DNA. Lane 2, nicked pUC18. Lane 3, nicked
pUC18 and T4 DNA ligase. Lanes 4–8, nicked DNA and T4 DNA ligase
with 100, 500, 1000, 2000 and 3000 nM HMO2.
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[an interpretation based on reported diﬀerential dynamic
properties of DNA with diﬀerent base mismatches; e.g.,
ref. (41)], or inherent sequence preferences of HMO2.
Complex formation was generally more deﬁned in
presence of detergent as HMO2 self-associates in its
absence (not shown); we therefore also had to consider
the possibility that equilibrium binding conditions
include a contribution from monomeric HMO2 dissociating from a larger aggregate when diluted from a
concentrated stock solution, even in the presence of detergent, and we elected not to calculate a binding constant.
Such self-association was also noted for the yeast HMGB
homolog HMO1 (31,37,38). With the 37 bp DNA duplex
with tandem loops, HMO2 forms an unstable but detectable complex, while no preferred binding was seen to 37 bp
DNA with a single nick, gap or overhang (consistent
with the observation that HMO2 binds preferentially to
50 bp DNA with two separate lesions; data not shown).
In contrast to HMO1, HMO2 also does not form a detectable complex with 26 bp DNA (37). Evidently, HMO2
binds preferentially to DNA with a pair of lesions, but
only in duplex DNA of suﬃcient length. On removal
of the N-terminal His6-tag, no diﬀerence was observed
in DNA binding indicating that the presence of the
His6-tag does not interfere with DNA binding (data not
shown).
HMGB proteins generally also have higher aﬃnity for
four-way junction DNA compared to perfect duplex
DNA, provided the absence of Mg2+, which would
induce a disfavored stacked X conformation of the
junctions (42–44). HMO2, however, has only a modest
preference for the four-way DNA junctions in absence
of Mg2+ (Figure 2E) compared to perfect duplex DNA
and forms complex comparable to that seen with DNA
containing a single lesion.
To ascertain whether HMO2 binds preferentially to
supercoiled DNA, a competition assay was performed
by incubating 5 fmol 50 bp looped DNA and 4 mM
HMO2, following which 0.5–50 fmol of supercoiled or
linearized pGEM5 was added to the reaction. Evidently,
supercoiled DNA competes more eﬃciently (Figure 3);
HMO2 forms a distinct complex with the looped DNA
while supercoiled DNA competes as indicated by disappearance of the preformed complex. The linearized DNA
does not compete at equivalent concentrations whether

the DNA has 50 overhangs, 30 overhangs or blunt ends
(Figure 3B and data not shown; note that the concentration of free DNA ends is at most 10 nM, well below the
concentration of HMO2, while the concentration of internal sites would be more than two orders-of-magnitude
higher, assuming a 20 bp site size). This suggests that
HMO2 binds to supercoiled DNA with higher aﬃnity
compared to linearized DNA. Taken together, our data
indicate that HMO2 resembles mammalian HMGB
proteins in its preferred binding to supercoiled DNA or
DNA with tandem mismatches, but that it distinguishes
itself by its requirement for a longer DNA duplex and
its preference for DNA with a pair of lesions.
HMO2 binds DNA ends
HMGB proteins have been reported to promote DNA
end-joining in vitro (26,27). The in vivo correlate would
be that during DSB repair, HMGB might bring two
DNA ends in closer proximity in preparation for either
HR or NHEJ. HMO2, however, did not promote the formation of end-joined products in the presence of T4 DNA
ligase. Instead, HMO2 prevented end-joining of DNA
with a 50 -TA extension (Figure 4A) or DNA with blunt
ends (Figure 4B). In Figure 4A and B, lane 2 shows 100 ng
(4 nM) linearized DNA ligated in presence of T4 DNA
ligase. But in presence of HMO2 (0.1–4 mM; lanes 3–8)
there are few if any end-joined products. By comparison,
100 ng plasmid DNA (2 nM) may be eﬃciently ligated in
the presence of mammalian HMGB1, with optimal
ligation eﬃciency seen on addition of 1 mM HMGB1
(26). Notably, lane 9 suggests that the DNA is resistant
to exonuclease III digestion in the presence of HMO2 and
T4 DNA ligase. The failure to observe ligation products in
presence of HMO2 as well as the inability of exonuclease
III to digest the DNA suggests that HMO2 may be
binding to the ends of the DNA duplex to prevent
access to both T4 DNA ligase and exonuclease III. Also
note that failure to join DNA ends is not due to HMO2
merely interacting with the ligase to prevent its activity, as
evidenced by the activity of T4 DNA ligase on an internal
DNA nick in the presence of HMO2 (Figure 1C).
To examine further a potential DNA end-binding
by HMO2, DNA with a 2-nt 50 -TA extension or blunt
ends (Figure 5A) and DNA with a 2-nt 30 -AT extension
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Figure 3. HMO2 binds preferentially to supercoiled DNA compared to linear DNA. (A) Reactions with 5 fmol of 50 bp looped DNA and 4 mM
HMO2. Lane 1, DNA only, lanes 2, 50 bp looped DNA and 4 mM HMO2. Lanes 3–11 with 0.5–50 fmol supercoiled pGEM5. (B) Titration with
linear pGEM5 with 50 overhangs.
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(Figure 5B) was treated with exonuclease III in presence of
HMO2. Exonuclease III reactions are terminated with
SDS, and a control in which HMO2 is incubated with
DNA in absence of exonuclease III is included (lane 3);
in the latter reactions, the original DNA is quantitatively
recovered upon treatment with SDS, indicating complete
disruption of the HMO2–DNA complex, which would
otherwise be manifest as a mobility shift as seen in
Figure 1. Figure 5A, lanes 2 and 6 and Figure 5B, lane
2, shows DNA with 50 overhangs, blunt ends and 30
overhangs digested extensively by exonuclease III. But in
presence of HMO2, the DNA is protected (Figure 5A,
lanes 4 and 8; B, lane 4). Since HMO2 obviously
prevents the formation of partial digestion products, as
it prevents the more extensive digestion seen on prolonged
incubation with exonuclease III, we elected to show only
the time-point at which exonuclease III has digested
unprotected DNA to such an extent that no individual
bands are discernible. These data suggest that HMO2
may be binding to both DNA with 50 and 30 overhangs
or blunt ends and preventing exonuclease III from
accessing the ends.
If HMO2 binds stably to DNA ends, preventing access
of both T4 DNA ligase and exonuclease III, then the
expectation would have been for stable complex formation
with 50 bp DNA duplex. This is not observed (Figure 2A).
Furthermore, we do not observe protection of 50 bp DNA
from exonuclease III-digestion in the presence of HMO2
(data not shown). We therefore considered that the 50 bp
DNA might be too short to accommodate HMO2 stably
at both ends simultaneously. To address this question,
plasmid DNA was digested with assorted enzymes to
yield fragments of diﬀerent sizes. When plasmid pET5a
is digested with BspHI, four fragments are produced
that contain 50 -CATG extensions. However, when incubated with HMO2 and exonuclease III, no protection is
observed (Figure 6A, lane 4), while DNA with 50 -TA

extension is protected from exonucleolytic digestion
(lane 8). Consistent with the inability of HMO2 to
protect DNA with BspHI-generated 50 overhangs, such
DNA may be re-ligated in presence of T4 DNA ligase
(Figure 6B, lane 3; lanes 1 and 2 contain DNA without
and with T4 DNA ligase, respectively). That ligation
products obtained in the presence of HMO2 migrate
diﬀerently compared to those created in its absence may
suggest either that HMO2 still binds with suﬃcient aﬃnity
to the 50 -CATG overhangs to compete with ligase for
binding or that binding to internal sites results in a
DNA conformation that favors formation of a diﬀerent
population of ligation products. Since DNA with
50 -AATT extensions is eﬃciently protected (Figure 6C),
our data suggest that it is the sequence of the overhangs
that aﬀects HMO2 binding. The diﬀerential protection of
DNA of comparable length, but with distinct sequence of
the single-stranded overhang, clearly indicates that HMO2
recognizes speciﬁc features of DNA ends.
To determine the DNA length required for eﬃcient
protection by HMO2, we therefore used enzymes that
produce blunt ends or A+T-containing overhangs. A
pCDNA3-derivative when linearized with ApoI produces
the following sizes of DNA, 127, 187, 811, 848, 1444, 1475
and 2277 bp. Figure 6C, lane 4 shows that HMO2 could
eﬃciently protect 811, 848, 1444, 1475 and 2277 bp but
was unable to protect 127 and 187 bp DNA, indicating
that a suitable size of the DNA is important for HMO2
in order to protect it from exonucleolytic cleavage.
Consistent with this observation, HMO2 was able to
protect 339, 692 and 713 bp fragments of pRAD1
linearized with DraI (data not shown). This suggests
that not only the size of the DNA but also the sequence
of the DNA overhang is important for HMO2 to bind and
protect the DNA.
The failure to protect short DNA from exonuclease III
digestion, even if single-stranded overhangs are otherwise
compatible with HMO2-binding, predicts that such
duplexes should be ligatable in presence of HMO2. We
therefore performed an end-joining assay using 105 bp
DNA with 50 -AATT overhangs. Figure 6D shows that
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Figure 4. HMO2 prevents ligation of DNA by T4 DNA ligase. (A) DNA
with overhangs (50 -TA extensions). (B) DNA with blunt ends. Lanes 1,
100 ng of DNA (4 nM, corresponding to 8 nM DNA ends). Lane 2,
DNA and T4 DNA ligase. Lanes 3–8, DNA, T4 DNA ligase with 100,
500, 1000, 2000, 3000 and 4000 nM HMO2. Lane 9, DNA, T4 DNA
ligase, 4000 nM HMO2 and exonuclease III.

Figure 5. HMO2 protects DNA with overhangs or blunt ends from
exonucleolytic cleavage. (A) Lanes 1–4 and 5–8, DNA with 2-nt
50 -TA extensions (4 nM) and blunt ends (2 nM), respectively.
Lanes 1 and 5, DNA only. Lanes 3 and 7, DNA and 2000 nM
HMO2. Lanes 2 and 6, DNA treated with exonuclease III for 1 h.
Lanes 4 and 8, DNA with 1000 nM HMO2 incubated with exonuclease
III for 1 h. (B) DNA with 2-nt 30 -AT extensions (4 nM). Lane 1,
DNA only. Lane 2, DNA treated with exonuclease III for 1 h. Lane
3, DNA with 2-nt 30 overhangs and 2000 nM HMO2. Lane 4, DNA
incubated with HMO2 and exonuclease III for 1 h.
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HMO2 promotes DNA dimer formation in presence of T4
DNA ligase (lanes 3–5). Similar reactions with B. subtilis
HU indicate formation of monomer circle, as evidenced
by its protection from exonuclease III digestion (lanes
6 and 7). Lane 8 indicates that ligation products with
105 bp obtained in presence of HMO2 cannot be protected
from exonuclease III. This experiment not only conﬁrms
the inability of HMO2 to associate with the ends of short
DNA in a manner that prevents access to ligase and
exonuclease III, but it also reveals that HMO2 does not
promote cyclization of short DNA. Whether this reﬂects
an inability of HMO2 to bend DNA, the association of
several HMO2 protomers causing out-of-phase bending,
or preferred binding to DNA ends remains to be
determined.
To rule out the possibility that HMO2 may coat or
compact the entire DNA, thereby rendering the majority
of the DNA resistant to exonuclease digestion, we assessed
whether HMO2–DNA complexes are also resistant to
endonucleolytic digestion. Supercoiled DNA or linear
DNA with overhangs or blunt ends were treated with
DNase I. Figure 7, lanes 2, 8 and 14 show DNA treated
with DNaseI wherein the DNA is digested extensively.

Figure 7. HMO2 does not protect supercoiled or linearized DNA from
endonucleolytic cleavage. Lanes 1–6, 7–12 and 13–18, supercoiled
DNA, DNA with overhangs and DNA with blunt ends, respectively
(4 nM). Lanes 1, 7 and 13, DNA only. Lanes 3, 9 and 15, DNA and
1000 nM HMO2. Lanes 2, 8 and 14, DNA treated with DNase I for
2.5 min. Lanes 4, 5 and 6, supercoiled DNA and 1000 nM HMO2
treated with DNase I for 1, 2.5 and 5 min. Lanes 10, 11 and 12,
DNA with overhangs and 1000 nM HMO2 treated with DNase I for
1, 2.5 and 5 min. Lanes 16, 17 and 18, DNA with blunt ends and
1000 nM HMO2 treated with DNase I for 1, 2.5 and 5 min.

In presence of HMO2, DNaseI is likewise able to digest
the DNA (lanes 4–6, 10–12 and 16–18). The inability of
HMO2 to attenuate endonucleolytic digestion is consistent with the interpretation that protection against
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Figure 6. DNA protection by HMO2 depends on DNA length and sequence of DNA overhangs. (A) DNA with G+C-containing overhangs is not
protected by HMO2. Lanes 1–4, DNA with 50 -CATG extensions (2 nM), lanes 5–8, DNA with 50 -TA extensions (4 nM). Lanes 1 and 5, DNA
only. Lanes 2 and 6, DNA treated with exonuclease III for 1 h. Lanes 3 and 7, DNA and 2000 nM HMO2. Lanes 4 and 8, DNA with 2000 nM
HMO2 incubated with exonuclease III for 1 h. Note in lane 8 the appearance of a product with lower mobility. Only the two largest fragments of
BspHI-digested pET5a are shown in lanes 1–4. (B) Ligation of DNA with 50 -CATG extension (2 nM). Lane 1, DNA only. Lane 2, DNA and T4
DNA ligase. Lane 3, DNA, T4 DNA ligase and 2.5 mM HMO2. (C) Length dependence of DNA protection by HMO2. Lane 1, DNA with 4-nt 50
overhangs. Lane 2, DNA treated with exonuclease III for 1 h. Lane 3, DNA and 2000 nM HMO2. Lane 4, DNA incubated with HMO2 and
exonuclease III for 1 h. (D) HMO2 can end-join 105 bp DNA in presence of T4 DNA ligase. Lane 1, 100 fmol of 105 bp DNA. Lane 2, 105 bp DNA
and T4 DNA ligase. Lanes 3–5, 105 bp DNA, T4 DNA ligase and 100, 250 and 500 nM HMO2. Lane 6, 105 bp DNA, T4 DNA ligase and 100 nM B.
subtilis HU (HBsu). Lane 7, 105 bp DNA, T4 DNA ligase, 100 nM B. subtilis HU and exonuclease III. Lane 8, 105 bp DNA, T4 DNA ligase, 250 nM
HMO2 and exonuclease III.
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exonuclease III-mediated digestion is due to end-binding
by HMO2, not continuous protection of internal sites.
To document further that the very stable binding to
DNA ends that is characteristic of HMO2 is unique and
not a general property of the yeast HMGB proteins, we
performed the equivalent assays with HMO1. As shown in
Figure 8, properties of HMO1 are more akin to those of
mammalian HMGB1; it does promote the association of
DNA ends in the presence of DNA ligase (Figure 8A), but
it either does not bind to DNA ends or does so only
transiently to allow eﬃcient access to exonuclease III, as
evidenced by its failure to protect linearized pGEM5
with 2-nt 50 overhangs from exonucleolytic cleavage
(Figure 8B, lanes 4–6).
DISCUSSION
Preferential binding to distorted DNA
The occluded DNA site size for an HMG domain is
10 bp (19–23). Since HMO2 has two domains, Box A
and Box B, it would be predicted to require at least a
20 bp DNA site; indeed, the yeast HMGB homolog
HMO1, which also features two HMG-like domains,
binds poorly to 18 bp DNA, but with signiﬁcantly higher
aﬃnity to 26 bp DNA (37). However, our data suggest
that HMO2 binds only weakly to 37 bp DNA with loops
(data not shown) and with much greater aﬃnity to 50 bp
looped DNA (Figure 2). For the Box B domain, which has
high homology to mammalian HMGB proteins, interaction with a 10 bp site is a strong prediction. Although the
Box A domain diﬀers from consensus HMG sequences, its
similarity to the HMO1 Box A domain, which also diﬀers
from consensus sequences, yet interacts with an 10 bp

DNA-end binding
Consistent with its preferred binding to negatively supercoiled DNA, HMO2 produces DNA supercoils, due either
to DNA underwinding or out-of-plane bending. And as
noted above, its preferred binding to DNA loops likely
reﬂects the energetic advantage to bending DNA with
ﬂexible joints. In these interactions, HMO2 emulates
properties of mammalian HMGB homologs. What is
unique about HMO2 is its remarkable ability to protect
certain DNA constructs from exonucleolytic cleavage and
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Figure 8. HMO1 promotes DNA end-joining, but does not protect
DNA from exonucleolytic cleavage. (A) HMO1 can promote endjoining of pGEM5 DNA with 2-nt 50 overhang in presence of T4
DNA ligase. Lane 1, 100 ng DNA only. Lane 2, DNA and T4 DNA
ligase. Lanes 3–5, DNA, T4 DNA ligase, and 500, 1000 and 2000 nM
HMO1, respectively. (B) HMO1 is unable to protect DNA with 2-nt 50
overhangs from exonuclease III. Lane 1, 100 ng DNA only. Lane 2,
DNA and exonuclease III. Lane 3, DNA and 500 nM HMO1. Lanes
4–6, DNA, exonuclease III, and 500, 1000 and 2000 nM HMO1,
respectively.

site, likewise predicts an 10 bp site. Based on these
assumptions about the site sizes for Box A and Box B, a
50 bp DNA construct would be of suﬃcient length to
accommodate a dimer; this interpretation does not necessarily imply that HMO2 likewise binds perfect duplex
DNA as a dimer, as the loops may potentially impose a
constraint, such as preferred binding to the 4-nt loop by
only one of the two protein domains.
HMGB proteins have been previously shown to bind
DNA with loops (40,45). The binding preference for
DNA with ﬂexure points is a functional correlate of the
DNA bend introduced on interaction with an HMG
domain, and the prediction is that HMO2 likewise bends
its DNA site. HMGB proteins also bind preferably to
four-way DNA junctions (42–44); while HMO2 does
bind four-way DNA junctions in preference to a linear
DNA duplex (compare Figure 2A and E), the preference
is modest. For mammalian HMGB1, binding to four-way
DNA junctions is mediated by the Box A domain (44).
This selectivity arises from using a hydrophobic residue
from helix II of the HMG fold as a bending wedge; the
greater preference for distorted DNA is due to stacking of
this residue on an exposed base pair. In contrast, mammalian HMGB1 Box B has bending wedges in both helices
I and II of the HMG fold and is primarily responsible for
DNA bending, whereas its aﬃnity for distorted DNA is
only modestly higher than that for perfect duplex DNA.
By comparison, HMO2 is also predicted to feature a
bending wedge (Leu) in helix II of its Box A domain,
suggesting that this domain contributes the binding preference for distorted DNA. For HMO2 Box B, a leucine in
helix I would be predicted to be the DNA intercalating
residue.
Like other HMGB proteins, HMO2 binds preferentially
to supercoiled DNA compared to linear DNA (Figures 1
and 3). The DNA–protein complex with highest [HMO2]
migrates faster in the gel (Figure 1, lanes 6 and 7), suggesting that HMO2 might play a role in DNA compaction. This observation is consistent with the ability of
HMO2 to introduce supercoils and with the enhanced
staining of HMO2-bound DNA by ethidium bromide
that may also reﬂect DNA unwinding by HMO2. While
nuclear HMGB proteins have not been shown to compact
DNA in vitro as determined by changes in electrophoretic
mobility, Abf2p, a protein closely related to the HMG
family, has been shown to compact mitochondrial DNA
(46). Long-range DNA looping created by protein–protein
contacts, however, has been shown to produce more
compact DNA structures (47).
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proteins, again without restricting access of DNA ends to
DNA ligase (48). Based on these observations and considerations, we therefore conclude that HMO2 exerts its
protection against exonuclease III by binding to the
DNA ends.
If DNA with complementary overhangs were to anneal,
a duplex with nicks would be produced. However, it can
also be ruled out that HMO2 merely binds preferentially
to such nicked DNA constructs to prevent their ligation,
as short DNA with equivalent overhangs may be ligated
(Figure 6D). Nicked plasmid DNA may likewise be
ligated in the presence of HMO2 (Figure 1C). Indeed,
the enhanced ligation of 105 bp DNA in the presence of
HMO2 suggests that HMO2 may also bind the ends of the
shorter DNA, albeit less stably, as reﬂected in its inability
to protect such duplexes from exonucleolytic digestion.
That HMO2 promotes DNA end-joining in the presence
of DNA ligase may also be related to the occasional
appearance of more slowly migrating DNA species following incubation of linear DNA with both HMO2 and
exonuclease III (Figure 6A, lane 8); since these reactions
are deproteinized and no ligase is present, we surmise that
long single-stranded overhangs generated by exonuclease
may invade a complementary duplex in presence of
HMO2 to generate a merged structure that is stable to
the subsequent manipulations. This possibility is currently
under investigation.
Recently, HMO2 was reported to be a part of the ATPdependent chromatin-remodeling complex INO80 and to
be important for recruitment of the INO80 complex to a
DSB (3). Arrival of the INO80 complex is predicted to be
a part of the early response to DSB formation. In both
mammalian and yeast cells, a complex containing the Ku
heterodimer and DNA ligase is capable of rejoining
DNA DSBs with compatible ends via NHEJ, while
DNA with damaged ends requires additional factors
(2,4). Furthermore, NHEJ and HR events interfere with
each other; for example, a Rad51 ﬁlament forms on singlestranded DNA in preparation for HR and impedes NHEJ
(49). It is conceivable, therefore, that HMO2, in addition
to its role in INO80 recruitment, also contributes to the
protection of DNA ends that is essential to preserve the
genetic information before DSB repair can be completed.
In its complex with INO80 components, HMO2 was
reported to interact with phosphorylated histone H2A,
indicating that it is not buried in the complex, but accessible for interaction with chromatin. It is therefore likely
that it would also be accessible for binding to naked
DNA. The preferred binding to DNA with blunt ends
or with A+T-containing overhangs may indicate diﬀerential functions depending on the type of DNA ends and the
DNA repair pathway; for example, yeast Rad51 binds
more slowly to single-stranded DNA with AT dinucleotide repeats compared to C- or G-containing dinucleotide
repeats (50), perhaps requiring accessory proteins to
protect such A+T-rich sequences.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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to prevent their end-joining in presence of T4 DNA ligase,
suggesting preferred binding to these DNA ends. DNA
with blunt ends is protected eﬃciently, while in case of
DNA with overhangs, the sequence of the single
stranded overhang signiﬁcantly aﬀects HMO2 binding
(Figures 5A, B, and 6A). Considering the preferred
binding of HMO2 to distorted DNA sites, its interaction
with DNA ends may likewise be a manifestation of preferred binding to more deformable duplex regions.
Mammalian HMGB1 has been reported to bind DNA
ends, but not to protect DNA ends from exonuclease
III, perhaps reﬂecting a more dynamic association with
the DNA ends (26). The ability of HMO2 to associate
more stably with DNA ends is perhaps attributable to
the divergent Box A domain which bears little resemblance to mammalian Box A.
It is also evident that HMO2 requires DNA of a
suitable length to bind and protect (Figure 6C). Since
HMO2 forms stable complex with plasmid DNA, but
not with 50 bp perfect duplex, and since it appears to
bind only as a dimer to 50 bp looped DNA, complex stability is likely a consequence of both DNA structure and
protein–protein interactions. Such interactions are likely
the reason for protection only of DNA long enough for
assembly of several protomers at each DNA end. Selfassociation was also reported for the yeast HMGB
homolog HMO1 as well as for mammalian HMGB1, for
which residues in the box B domain critical for its ability
to stimulate DNA end-joining were also important for box
B self-association on supercoiled DNA and the formation
of large nucleoprotein complexes (26,31,37).
If HMO2 were to protect DNA from exonuclease III
digestion largely by occluding essentially the entire DNA,
except for a limited number of base pairs at the ends, then
protection from endonuclease digestion might also be
seen. However, no such protection is observed (Figure
7). For this interpretation to be considered, one would
also expect that all DNA fragments, regardless of
sequence of the DNA overhangs, would be protected
comparably. This is also not observed, as evidenced by
the failure of HMO2 to protect DNA with C- or
G-containing overhangs (Figure 6A and B). We also
note that ligation at an internal nick occurs in the
presence of HMO2 (Figure 1C). For HMO2 to bend
internal sites, thereby restricting access to exonuclease
III and DNA ligase is likewise unlikely; ﬁrst, attenuated
access to endonuclease would again be expected, as would
protection of DNA fragments regardless of sequence of
DNA overhangs. If signiﬁcant out-of-phase bending
occurred upon HMO2 binding, this could stiﬀen DNA
and prevent net DNA bending, resulting in preferential
generation of linear ligation products in preference to
circular products, an eﬀect likely to be most pronounced
using shorter DNA fragments as opposed to plasmid
DNA. Indeed, facilitated cyclization of short DNA
fragments in presence of a DNA-bending protein is
commonly used as an assay for DNA bending, without
internal DNA bends restricting access of DNA ligase to
DNA ends (27,37). In-phase bending might lead to
compaction; such compacted DNA may be produced by
both HMGB homologs and the bacterial histone-like HU
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